

United States Uterine Fibroids Treatment Devices Market By Mode of Treatment (Invasive Treatment, Minimally Invasive Treatment, Non-invasive Treatment), By Technology (Surgical Techniques, Laparoscopic Techniques, Ablation Techniques, Others), By Region and Competition, Forecast & Opportunities, 2020-2030F

Market Report | 2025-04-11 | 85 pages | TechSci Research

AVAILABLE LICENSES:

- Single User License \$3500.00
- Multi-User License \$4500.00
- Custom Research License \$7000.00

Report description:

The U.S. Uterine fibroids treatment devices market was valued at USD 512.35 million in 2024 and is projected to reach USD 776.73 million by 2030, expanding at a compound annual growth rate (CAGR) of 7.38% during the forecast period. This market is witnessing steady growth, fueled by increasing awareness of minimally invasive procedures, ongoing technological advancements, and the rising prevalence of uterine fibroids among women of reproductive age.

As both healthcare providers and patients increasingly seek effective, non-invasive, and patient-centric treatment options, the demand for advanced devices continues to grow. Uterine fibroids, or leiomyomas, impact a substantial proportion of women in the United States, particularly those aged 30 to 50. The escalating number of diagnosed cases is driving the need for advanced therapies, ranging from surgical interventions to minimally invasive procedures. Although these innovative treatments offer several benefits, the high cost associated with advanced devices and related procedures remains a significant barrier to broader adoption-especially in smaller or under-resourced healthcare facilities. Technologies such as magnetic resonance-guided focused ultrasound (MRgFUS) and robotic-assisted surgeries involve substantial initial investment, which may limit accessibility.

Key Market Drivers

Expansion of the Healthcare Sector

The growing healthcare industry in the United States is a key catalyst for the uterine fibroids treatment devices market. This growth is underpinned by rising healthcare expenditures, medical technology advancements, and increased patient awareness. In 2022, healthcare spending in the U.S. represented approximately 17.8% of the national Gross Domestic Product (GDP), significantly higher than the 11.5% average among other high-income nations. Healthcare coverage, however, remains uneven, with more comprehensive access available to populations such as the elderly, disabled, and low-income individuals through

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

programs like Medicare and Medicaid.

As the nation's healthcare infrastructure continues to develop and access to specialized treatments becomes more widespread, the demand for minimally invasive and technologically advanced uterine fibroids treatment options is accelerating. A primary growth driver is the high prevalence of fibroids among women in the U.S.-with the Office on Women's Health (OWH) estimating that between 20% and 80% of women will develop fibroids by age 50. Consequently, there is an increasing shift toward non-surgical treatment solutions, including uterine artery embolization (UAE), MRgFUS, and laparoscopic radiofrequency ablation (RFA).

MRgFUS is a cutting-edge, non-invasive technology that utilizes geometrically focused, high-intensity ultrasound waves to target deep tissue structures without anesthesia or radiation exposure. It enables real-time imaging and precision targeting while offering additional capabilities, such as reversible blood-brain barrier (BBB) opening and neuromodulation, with potential applications extending to neurological conditions.

These advanced treatment modalities offer several clinical advantages, including shorter recovery periods, reduced complications, and improved patient outcomes, positioning them as favorable alternatives to traditional surgical procedures such as hysterectomy.

Key Market Challenges

High Costs Associated with Advanced Devices

The high cost of technologically advanced treatment devices remains a major constraint for market expansion. Devices such as MRgFUS, robotic-assisted surgical systems, and RFA tools incorporate complex engineering, high-resolution imaging technologies, and AI-integrated controls, resulting in significantly higher manufacturing and acquisition costs compared to conventional surgical instruments.

This cost barrier particularly impacts smaller hospitals and outpatient centers that may lack the capital resources to invest in these systems. Moreover, the procedures involving these devices often incur higher costs, which can result in elevated out-of-pocket expenses for patients-especially those with limited insurance coverage for emerging treatments. While these minimally invasive solutions reduce hospital stays and accelerate recovery, the financial burden continues to challenge widespread adoption.

Key Market Trends

Rising Awareness and Emphasis on Early Diagnosis

Heightened awareness of uterine fibroids and the growing importance of early diagnosis are shaping key trends in the U.S. market. The Early Detection Research Group (EDRG) supports initiatives evaluating the efficacy, performance, and clinical outcomes of early detection technologies, including advanced imaging and molecular diagnostics.

Educational campaigns, advocacy initiatives, and innovations in diagnostic methods are encouraging more women to seek early evaluation and intervention. This proactive approach is increasing demand for non-invasive treatment solutions. Public awareness efforts by organizations such as the Fibroid Foundation and the Society for Women's Health Research (SWHR) are playing a pivotal role in disseminating information about symptoms, diagnosis, and available treatments. These initiatives are helping to drive early diagnosis and improve access to less invasive therapeutic options.

Key Market Players

- [] Medtronic Plc
- [] Stryker Corporation
- [] Boston Scientific Corporation
- [] INSIGHTEC Ltd.
- [] CooperSurgical Inc.

Report Scope

In this report, the United States Uterine Fibroids Treatment Devices Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

- [] United States Uterine Fibroids Treatment Devices Market, By Mode of Treatment:
 - o Invasive Treatment
 - o Minimally Invasive Treatment

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- o Non-invasive Treatment
- United States Uterine Fibroids Treatment Devices Market, By Technology:
 - o Surgical Techniques
 - o Laparoscopic Techniques
 - o Ablation Techniques
 - o Others

- United States Uterine Fibroids Treatment Devices Market, By Region:
 - o Northeast
 - o Midwest
 - o South
 - o West

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the United States Uterine Fibroids Treatment Devices Market.

Available Customizations:

United States Uterine Fibroids Treatment Devices Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

- Detailed analysis and profiling of additional market players (up to five).

Table of Contents:

1. Product Overview
 - 1.1. Market Definition
 - 1.2. Scope of the Market
 - 1.2.1. Markets Covered
 - 1.2.2. Years Considered for Study
 - 1.2.3. Key Market Segmentations
2. Research Methodology
 - 2.1. Objective of the Study
 - 2.2. Baseline Methodology
 - 2.3. Key Industry Partners
 - 2.4. Major Association and Secondary Sources
 - 2.5. Forecasting Methodology
 - 2.6. Data Triangulation & Validation
 - 2.7. Assumptions and Limitations
3. Executive Summary
 - 3.1. Overview of the Market
 - 3.2. Overview of Key Market Segmentations
 - 3.3. Overview of Key Market Players
 - 3.4. Overview of Key Regions/Countries
 - 3.5. Overview of Market Drivers, Challenges, Trends
4. United States Uterine Fibroids Treatment Devices Market Outlook
 - 4.1. Market Size & Forecast
 - 4.1.1. By Value
 - 4.2. Market Share & Forecast
 - 4.2.1. By Mode of Treatment (Invasive Treatment, Minimally Invasive Treatment, Non-invasive Treatment)
 - 4.2.2. By Technology (Surgical Techniques, Laparoscopic Techniques, Ablation Techniques, Others)

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 4.2.3. By Region
- 4.2.4. By Company
- 4.3. Market Map
- 4.3.1. By Mode of Treatment
- 4.3.2. By Technology
- 4.3.3. By Region
- 5. Northeast Uterine Fibroids Treatment Devices Market Outlook
- 5.1. Market Size & Forecast
- 5.1.1. By Value
- 5.2. Market Share & Forecast
- 5.2.1. By Mode of Treatment
- 5.2.2. By Technology
- 6. Midwest Uterine Fibroids Treatment Devices Market Outlook
- 6.1. Market Size & Forecast
- 6.1.1. By Value
- 6.2. Market Share & Forecast
- 6.2.1. By Mode of Treatment
- 6.2.2. By Technology
- 7. South Uterine Fibroids Treatment Devices Market Outlook
- 7.1. Market Size & Forecast
- 7.1.1. By Value
- 7.2. Market Share & Forecast
- 7.2.1. By Mode of Treatment
- 7.2.2. By Technology
- 8. West Uterine Fibroids Treatment Devices Market Outlook
- 8.1. Market Size & Forecast
- 8.1.1. By Value
- 8.2. Market Share & Forecast
- 8.2.1. By Mode of Treatment
- 8.2.2. By Technology
- 9. Market Dynamics
- 9.1. Drivers
- 9.2. Challenges
- 10. Market Trends & Developments
- 10.1. Recent Developments
- 10.2. Product Launches
- 10.3. Mergers & Acquisitions
- 11. Policy & Regulatory Landscape
- 12. United States Economic Profile
- 13. Competitive Landscape
- 13.1. Medtronic Plc
- 13.1.1. Business Overview
- 13.1.2. Company Snapshot
- 13.1.3. Products & Services
- 13.1.4. Financials (In case of listed)
- 13.1.5. Recent Developments
- 13.1.6. SWOT Analysis

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 13.2. Stryker Corporation
- 13.3. Boston Scientific Corporation
- 13.4. INSIGHTEC Ltd.
- 13.5. CooperSurgical Inc.
- 14. Strategic Recommendations
- 15. About us & Disclaimer

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

United States Uterine Fibroids Treatment Devices Market By Mode of Treatment (Invasive Treatment, Minimally Invasive Treatment, Non-invasive Treatment), By Technology (Surgical Techniques, Laparoscopic Techniques, Ablation Techniques, Others), By Region and Competition, Forecast & Opportunities, 2020-2030F

Market Report | 2025-04-11 | 85 pages | TechSci Research

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$3500.00
	Multi-User License	\$4500.00
	Custom Research License	\$7000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Date

2025-05-06

Signature



Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com